BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PROLOR Biotech (PBTH) Announces Pricing of Public Offering of Common Stock


5/14/2012 10:22:02 AM

NES-ZIONA, Israel, May 11, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH; TASE: PBTH), today announced the pricing of its previously announced underwritten public offering of 6.5 million shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to PROLOR from this offering are expected to be $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by PROLOR. PROLOR has granted the underwriters a 30-day option to purchase up to an aggregate of 975,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on May 16, 2012, subject to customary closing conditions. Jefferies & Company, Inc. is acting as the sole book-running manager and Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE AMEX: LTS), and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

PROLOR intends to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, including expenses related to clinical trials, capital expenditures, working capital, and general and administrative expenses. PROLOR may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.

The offering is being made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission, or SEC, which the SEC declared effective on April 26, 2012. Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement and other documents PROLOR has filed with the SEC, for more complete information about PROLOR and this offering. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by telephone at 877 547-6340, or by email at Prospectus_Department@Jefferies.com or to Ladenburg Thalmann & Co. Inc., 520 Madison Avenue, 9th Floor, New York, NY 10022, or by telephone at 212 409-2000, or by email at CorporateRelations@ladenburg.com, or to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at 212 667-8563, or by email at EquityProspectus@opco.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About PROLOR
PROLOR Biotech, Inc. is a development stage biopharmaceutical company utilizing patented technology to develop longer-acting, proprietary versions of already-approved therapeutic proteins that currently generate billions of dollars in annual global sales.

Safe Harbor Statement: In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to PROLOR's expectations regarding the completion, timing and size of its public offering and the expected net proceeds therefrom. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with PROLOR's business and finances in general, and the other risks described in PROLOR's annual report on Form 10-K for the year ended December 31, 2011, as amended, and quarterly report on Form 10-Q for the quarter ended March 31, 2012. PROLOR undertakes no obligation to update the statements contained in this press release after the date hereof.

PROLOR CONTACT:

MEDIA CONTACT:

Investor Relations

Barbara Lindheim

PROLOR Biotech, Inc.

BLL Partners, LLC

Tel: +1 866 644-7811

+1 212 584-2276


blindheim@bllbiopartners.com

SOURCE PROLOR Biotech, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->